COVID-19: A potential treatment for loss of smell
Covid-19 is known to cause loss of smell in certain patients. While this symptom is generally temporary, approximately 10% of patients may suffer from it for 6 months or more.
Earlier research carried out by a team of researchers from INRAE and ENVA observed that the SARS-CoV-2 infected olfactory mucosa is invaded by immune cells leading to its destruction and prolonged inflammation. Based on these observations, the same team decided to assess the effectiveness of corticosteroids--known for their anti-inflammatory properties—in restoring the sense of smell.
Their results support the existence of a direct link between the loss of smell caused by the virus and a decrease in the olfactory neuron population in the nasal mucosa. In addition, they show that early treatment with dexamethasone, a commonly used corticosteroid, improves the recovery of olfactory abilities in animals.
The improvement of the olfactory capacities is associated with a reduction of the immunity cells in the mucosa, and an increased level of regeneration of the olfactory neuron population. These results suggest that the corticosteroid treatments currently used—which have not been very successful in the treatment of prolonged anosmia—could be more effective if prescribed early, at the onset of symptoms of loss of smell.
Original publication
Original publication
Laetitia Merle-Nguyen, Ophélie Ando-Grard, Clara Bourgon, Audrey St Albin, Juliette Jacquelin, Bernard Klonjkowski, Sophie Le Poder, Nicolas Meunier; "Early corticosteroid treatment enhances recovery from SARS-CoV-2 induced loss of smell in hamster"; Brain, Behavior, and Immunity, Volume 118
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Leprosy strain genotyped from medieval pilgrim at UK burial site - Medieval leprosy victim in UK cemetery was likely a religious pilgrim, possibly from overseas
Thermo Fisher Scientific Forms Consortium to Drive Immunotherapy Research Across Europe
Europe challenges USA in stem cell research

Overcome food allergies and sensitivities - Ukko secures USD 40 million in Series B funding led by Leaps by Bayer

Supermicroscope for Protein Crystals - Combination of techniques locates microcrystals for structural analysis

This one-atom chemical reaction could transform drug discovery - This nearly unprecedented work could simplify and lower the cost of pharmaceutical synthesis

Tailor-made Metal Complexes for Medical Diagnostics and Therapy - Chemists study manganese, lutetium, and actinium compounds for potential applications in medicine

Antimicrobial resistance is drastically rising
€10 million for developing sustainable raw materials for chemical industry
